Hypoxia and COVID-19 Pathophysiology at High Altitude

High-altitude environments present a unique interplay between reduced atmospheric pressure, low arterial oxygenation and the host response to SARS-CoV-2 infection. Chronic hypoxia at elevation drives adaptive mechanisms such as increased erythropoiesis, pulmonary vasoconstriction and enhanced hypoxia-inducible factor (HIF) signalling. These adaptations may alter viral entry and replication, modulate inflammatory cascades and affect microvascular function. Observational data from diverse populations suggest that residents at moderate to high altitudes often experience lower COVID-19 incidence, attenuated severity and reduced mortality compared with lowland counterparts. Proposed mechanisms include downregulation of angiotensin-converting enzyme 2 (ACE2) receptor density in hypoxic tissues, HIF-mediated suppression of viral replication and shifts in immune cell metabolism that temper cytokine release. At the same time, hypobaric hypoxia may exacerbate acute respiratory distress syndrome (ARDS) and pulmonary hypertension in severe cases, underlining the need for tailored clinical strategies and ventilatory support adapted to altitude physiology.

Research from Nature Portfolio

Studies using in vitro models of SARS-CoV-2-induced acute respiratory distress and pulmonary fibrosis have revealed that HIF-1α is a central mediator of pro-inflammatory cytokine production and fibroproliferative responses under low-oxygen conditions. Knockdown of HIF-1α in macrophage and fibroblast cell lines markedly reduces interleukin-6, interleukin-1β and transforming growth factor-β signalling, while application of a dietary flavonoid inhibitor curbs collagen deposition and myofibroblast activation, pointing to HIF-1α as a potential therapeutic target for mitigating hypoxia-driven lung injury. Separate work examining the impact of reduced barometric pressure on respiratory support equipment highlights that ventilators calibrated at sea level may under-deliver tidal volumes at elevation. This finding has prompted calls for altitude-specific design and testing of ventilatory systems to ensure effective oxygenation and minimise ventilator-induced lung injury in high-altitude populations.

Hypoxia and COVID-19 Pathophysiology at High Altitude publication trend

The graph below shows the total number of articles in hypoxia and covid-19 pathophysiology at high altitude across all publications each year (not limited to Nature Index journals).

Technical terms

Hypoxia: A state of reduced oxygen availability at the tissue or cellular level.

Hypoxia-inducible factor-1α (HIF-1α): A transcription factor activated by low oxygen tension that regulates genes involved in metabolism, angiogenesis and inflammation.

Barometric pressure: The atmospheric pressure exerted by the weight of air, which decreases with elevation.

Acute respiratory distress syndrome (ARDS): A severe form of lung injury characterised by widespread inflammation, alveolar flooding and impaired oxygenation.

Angiotensin-converting enzyme 2 (ACE2): A cell-surface enzyme that serves as the entry receptor for SARS-CoV-2 and modulates the renin–angiotensin system.

References

1. Effect of apigetrin in pseudo-SARS-CoV-2-induced inflammatory and pulmonary fibrosis in vitro model. Scientific Reports (2024).
2. A U-shaped protection of altitude against mortality and infection of COVID-19 in Peru: an ecological study. BMC Public Health (2023).
3. High-altitude populations need special considerations for COVID-19. Nature Communications (2020).
4. Hypoxic and pharmacological activation of HIF inhibits SARS-CoV-2 infection of lung epithelial cells. Cell Reports (2021).
5. Impact of altitude on COVID-19 infection and death in the United States: A modeling and observational study. PLOS ONE (2021).
6. Hypoxia reduces cell attachment of SARS-CoV-2 spike protein by modulating the expression of ACE2, neuropilin-1, syndecan-1 and cellular heparan sulfate. Emerging Microbes & Infections (2021).
7. High-altitude is associated with better short-term survival in critically ill COVID-19 patients admitted to the ICU. PLOS ONE (2022).